Updated Safety and Efficacy Data in the Phase 1 Trial of Patients With Mantle Cell Lymphoma (mcl) Treated With Bruton Tyrosine Kinase (btk) Inhibitor Zanubrutinib (bgb‐3111)
Year: 2019
Type: article
Abstract: Peer Reviewed
Source: Hematological Oncology
DOI: 10.1002/hon.55_2630
Authors: C.S. Tam, M. Wang, D. Simpson, S. Opat, G. Cull, J. Munoz, T.J. Phillips, W. Kim, S. Atwal, R. Wei, J. Huang, R. Elstrom, J. Trotman
Institutions: The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, The University of Texas MD Anderson Cancer Center, North Shore Hospital, Waitemata District Health Board, Monash Health, Monash University, The University of Western Australia, Sir Charles Gairdner Hospital, Banner MD Anderson Cancer Center, University of Michigan, Michigan Medicine, U-M Rogel Cancer Center, Samsung Medical Center, Sungkyunkwan University, BeiGene (China), The University of Sydney, Concord Repatriation General Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2952307708